DexCom stock gains 1.22 percent ahead of October earnings

Published on 10/05/2026 at 16:27 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

DexCom stock carries a USD 32.6 billion market value on October 5, 2026. Q2 revenue reached USD 1.3084 billion and 2026 guidance rose to USD 5.18-5.25 billion.

Schwarzweiß-Reportage: Forscher im Labor mit Glukosemonitor, dokumentarisch — Dexcom Inc. Schwarzweiß-Reportage zeigt Forscher im Labor mit Glukosemessung für ISIN US2521311074 Medizintechnik, Illustration mit AI erstellt.

DexCom (ISIN US2521311074) was trading at USD 86.40 on Nasdaq at 10:26 a.m. ET on October 5, 2026, up 1.22 percent from the prior close. The company is scheduled to report third-quarter results on October 29, 2026, according to Yahoo Finance.

October earnings set the checkpoint

The October report will test whether DexCom can extend the operating progress shown in its latest reported quarter. In the quarter ended June 30, 2026, revenue reached USD 1.3084 billion, up 13 percent from the prior year, while GAAP net income was USD 249.1 million and diluted GAAP earnings per share were USD 0.64, according to StockTitan.

The same release showed a 24.3 percent GAAP operating margin and a 25.1 percent non-GAAP operating margin for Q2 2026. DexCom also lifted its full-year revenue guidance to USD 5.18-5.25 billion, with non-GAAP operating margin guidance of 23.5-24 percent, according to StockTitan.

Analysts see further upside

Analyst expectations add a second benchmark before the October report. Gekko reported 18 Buy ratings and 1 Hold rating from 19 firms, with an average 12-month target of USD 95.08 on October 3, 2026; the target stands 9.1 percent above the October 5 price of USD 86.40, according to Gekko.

RBC Capital raised its DexCom target to USD 105 from USD 90 on October 1, 2026, while maintaining an Outperform rating, as reported by Markets Insider. That target is 21.5 percent above the October 5 price, leaving the earnings release as the next concrete test of the growth and margin case.

Stock remains below its yearly high

DexCom's USD 86.40 price on October 5, 2026, sits within a 52-week range of USD 54.11 to USD 92.59. The stock's market capitalization was USD 32.6 billion, with volume of 280,912 shares at 10:26 a.m. ET.

For investors, the central comparison is between the USD 5.18-5.25 billion revenue outlook and the USD 1.3084 billion quarterly result. The October 29 report can therefore clarify whether the raised annual range remains supported by revenue growth and operating leverage.